How is survodutide dosed?
Survodutide has no FDA-approved product and no prescribing information, so there is no label schedule to read. This page reads the Phase 2 and Phase 3 SYNCHRONIZE trial doses directly instead — the NCT number, phase, enrollment, and arms for each trial, with the adverse events reported alongside the dose that produced them.
Topic: Reading survodutide’s trial doses directly, since no label exists
Audience: Anyone comparing a survodutide dose figure against its actual trial source
Reading time: 8–10 minutes
No approved product exists
Survodutide has not been approved by the FDA, EMA, or any other major regulatory body, under any brand name, for any indication. The FDA has granted Breakthrough Therapy and Fast Track designations tied to its MASH program — a designation that speeds review, not an approval. There is no prescribing information, no boxed warning, and no approved dosage to defer to. Every figure on this page is a fact about a specific clinical trial — not a recommendation.
On this page
What survodutide is, and what it isn’t
Survodutide (BI 456906) is Boehringer Ingelheim and Zealand Pharma’s investigational glucagon receptor / GLP-1 receptor dual agonist. It has been studied in Phase 2 and Phase 3 trials across obesity, metabolic dysfunction-associated steatohepatitis (MASH) and steatotic liver disease (MASLD), and type 2 diabetes. None of that trial activity has produced an approved product: as of this page’s build, survodutide has no brand name, no NDA approval, and no regulatory filing decision from the FDA.
That is the same structural reason the retatrutide dosing guide reads differently from Mounjaro’s or Ozempic’s label pages. There is no prescribing information to read, so what follows is a report of what each trial itself administered and found — not a schedule. The survodutide profile covers the mechanism and broader research areas in more depth; this page exists specifically to read the trial doses and their reported adverse events side by side.
What the trials administered
Five trials met the bar for inclusion here: each has a checkable NCT number, a published phase, enrollment, and dose arms, and an endpoint result attributable to a specific document. Each trial is graded against Prof. Peptide’s standing citation convention — a claim is attributed when it resolves to a named, checkable source. All five grade as attributed, and unlike some trials on other investigational-compound pages on this site, all five here are peer-reviewed publications rather than topline company releases — the two Phase 3 trials published in June 2026, in the New England Journal of Medicine and Nature Medicine respectively.
Phase 2 — Obesity
NCT04667377le Roux CW, Steen O, Lucas KJ, et al. Lancet Diabetes Endocrinol. 2024;12(3):162–173.
Design: 46-week (20-week dose escalation, 26-week maintenance), randomized, double-blind, placebo-controlled, dose-finding trial at 43 centers in 12 countries, in adults aged 18–75 with a BMI of 27 kg/m² or higher, without diabetes.
Arms: 387 participants (actual enrollment, per the registry; the published analysis reports 386, with 309 across the four active-dose arms and 77 on placebo) randomized to once-weekly subcutaneous survodutide at 0.6 mg, 2.4 mg, 3.6 mg, or 4.8 mg, or placebo.
Endpoint reported: Mean body-weight change at week 46: up to −12% versus placebo at the higher doses. 55% of participants receiving the 4.8 mg dose achieved a weight reduction of 15% or more.
Adverse events reported at these doses: Gastrointestinal disorders were the most frequently reported adverse events, consistent with the GLP-1-receptor-agonist class; the trial's published safety conclusion describes the tolerability profile as similar to other GLP-1-class agents.
Attributed — published in a peer-reviewed journal, registered with a checkable NCT number, phase/N/arms independently confirmed against the ClinicalTrials.gov record.
Phase 2 — MASH and Fibrosis
NCT04771273Sanyal AJ, Bedossa P, Fraessdorf M, et al. N Engl J Med. 2024;391(4):311–319.
Design: 48-week (24-week rapid dose escalation, 24-week maintenance), randomized, double-blind, placebo-controlled trial in adults with biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) and fibrosis stages F1–F3.
Arms: 295 participants (actual enrollment, per the registry; the published analysis reports 293 randomly assigned participants who received at least one dose) randomized to once-weekly subcutaneous survodutide at a planned maintenance dose of 2.4 mg, 4.8 mg, or 6.0 mg, or placebo.
Endpoint reported: Histologic improvement of MASH with no worsening of fibrosis was met by 47% (2.4 mg), 62% (4.8 mg), and 43% (6.0 mg) of survodutide-treated participants, versus 14% on placebo (P<0.001) — a quadratic dose-response, with the 4.8 mg dose producing the strongest response.
Adverse events reported at these doses: Gastrointestinal adverse events were the most common, reported at every survodutide dose more frequently than on placebo, and generally mild to moderate.
Attributed — published in a peer-reviewed journal, registered with a checkable NCT number, phase/N/arms independently confirmed against the ClinicalTrials.gov record.
Phase 2 — Type 2 Diabetes
NCT04153929Blüher M, Rosenstock J, Hoefler J, Manuel R, Hennige AM. Diabetologia. 2024;67(3):470–482.
Design: 16-week, randomized, double-blind (open-label for the semaglutide comparator arm), placebo- and active-controlled, dose-finding trial in adults aged 18–75 with type 2 diabetes (HbA1c 7.0–10.0%, BMI 25–50 kg/m²) on background metformin.
Arms: 413 participants (matches the registry's actual enrollment) randomized across six survodutide dose groups (0.3 mg through 3.6 mg weekly-equivalent, including two twice-weekly regimens), an open-label semaglutide comparator arm, and placebo.
Endpoint reported: HbA1c fell by up to 1.71 percentage points across the survodutide dose groups, versus 1.47 percentage points on semaglutide. At the highest survodutide dose group, body weight fell 8.7%, versus 5.3% on semaglutide.
Adverse events reported at these doses: Adverse events were reported in 77.8% of survodutide-treated participants (mainly gastrointestinal), versus 52.5% on placebo and 52.0% on the open-label semaglutide arm — a materially higher rate than either comparator, per the trial's published safety data.
Attributed — published in a peer-reviewed journal, registered with a checkable NCT number, phase/N confirmed against the ClinicalTrials.gov record. This page reports the highest-dose-group figures rather than a full six-arm breakdown, since the publication's per-arm dose-to-label mapping was not independently re-verified line by line before this page was built.
SYNCHRONIZE-1 — Phase 3, Obesity
NCT06066515le Roux CW, Wharton S, Startseva E, et al. N Engl J Med. 2026;395(8):776–787.
Design: Phase 3, randomized, double-blind, placebo-controlled trial in adults with a BMI of 30 or higher, or 27 or higher with at least one obesity-related complication, excluding diabetes. The primary efficacy analysis used the treatment-regimen estimand, which accounts for early discontinuation, protocol-prohibited obesity medications, and a prolonged dose-escalation period.
Arms: 725 participants (241 at 3.6 mg, 242 at 6.0 mg, 242 on placebo; the registry's own actual-enrollment count is 726) randomized 1:1:1 to once-weekly subcutaneous survodutide adjusted up to 3.6 mg or 6.0 mg, or placebo, alongside lifestyle-modification counseling.
Endpoint reported: Mean body-weight change at week 76 (treatment-regimen estimand): −12.2% (3.6 mg, 95% CI −13.6 to −10.8), −13.0% (6.0 mg, 95% CI −14.4 to −11.6), versus −5.4% on placebo (95% CI −6.9 to −4.0), P<0.001 for both comparisons. 72.6% (3.6 mg) and 71.9% (6.0 mg) of participants achieved a weight reduction of 5% or more, versus 46.3% on placebo.
Adverse events reported at these doses: The most common adverse events were gastrointestinal symptoms, typically mild to moderate: reported in 80.9% (3.6 mg), 89.7% (6.0 mg), and 47.9% (placebo) of participants. No deaths were reported.
Attributed — published in a peer-reviewed journal (NEJM, June 2026), registered with a checkable NCT number, phase/N/arms independently confirmed against the ClinicalTrials.gov record. This is a completed peer-reviewed publication, not a topline company release.
SYNCHRONIZE-MASLD — Phase 3
NCT06309992Kaplan LM, Startseva E, le Roux CW, et al. Nat Med. 2026;32(8):2948–2958.
Design: 48-week, randomized, double-blind, placebo-controlled Phase 3 trial in adults with obesity and metabolic dysfunction-associated steatotic liver disease (MASLD), conducted at sites in the United States and Spain.
Arms: 216 participants (matches the registry's actual enrollment; the published analysis reports 146 on survodutide 6.0 mg and 70 on placebo) randomized to once-weekly subcutaneous survodutide 6.0 mg or placebo.
Endpoint reported: Co-primary endpoints both met: 84.2% of survodutide-treated participants achieved a liver-fat-content reduction of 30% or more by MRI-PDFF, versus 24.3% on placebo (P<0.0001); mean body-weight change was −12.2% on survodutide versus −1.0% on placebo (P<0.0001).
Adverse events reported at these doses: Gastrointestinal adverse events were the most common, commonly occurring during dose escalation and generally mild to moderate, per the trial's published safety data.
Attributed — published in a peer-reviewed journal (Nature Medicine, June 2026), registered with a checkable NCT number, phase/N confirmed against the ClinicalTrials.gov record. This is a completed peer-reviewed publication, not a topline company release.
Two further Phase 3 trials exist in the program — SYNCHRONIZE-2, in people with obesity and type 2 diabetes, and SYNCHRONIZE-CVOT, a long-term cardiovascular safety outcomes study — but as of this page’s build only their baseline characteristics have been published, with no efficacy result yet attributable to a checkable source. They are not reported here for that reason and may be added once results are published.
Is there a community-reported dose?
Prof. Peptide looked for a genuinely reportable community dosing convention — a figure attributed to a specific, checkable source describing what researchers or users actually report doing, distinct from the trial data itself. None was found for survodutide.
Every vendor and blog page found describing a “survodutide dosing protocol” states the same shape: a 0.3 mg starting dose, escalated to 3.6 mg or 6.0 mg over roughly 14 to 16 weeks. That figure is not an independent community finding — it is the SYNCHRONIZE-1 and SYNCHRONIZE-MASLD trials’ own escalation schedule, restated with no source cited on any of the pages that repeat it. Nothing distinct from the trial data above survived as a genuine convention, so nothing is presented as one here.
Compounding and research-grade survodutide
There is no approved survodutide product, so there is neither a branded version nor a lawful pharmacy-compounded version of one.
No FDA warning letter specifically naming survodutide was found. FDA’s own warning letter on GLP-1 compounding (“GLP-1 Solution,” reference 715883, dated September 9, 2025) names retatrutide specifically and states the grounds for its 503A and 503B ineligibility — but does not mention survodutide anywhere in its text. This page instead applies section 503A’s published criteria to survodutide directly: a bulk drug substance is eligible for compounding only if it complies with a USP or NF monograph, is a component of an FDA-approved drug, or appears on FDA’s 503A bulks list. Checked directly against FDA’s own 503A and 503B bulk drug substance list pages on the date this page was built, “survodutide” and “BI 456906” appear on neither list, in any category. Survodutide has no USP or NF monograph (it is investigational, with no approved product to be a monograph subject of) and is not a component of any FDA-approved drug. None of the three conditions is met.
That is a different regulatory situation from semaglutide and tirzepatide during their supply shortages. Both of those had an approved brand-name product already on the market, which is what opened a temporary compounding pathway under sections 503A and 503B once the drug appeared on FDA’s drug shortage list. Survodutide was never an approved product, so that pathway has never applied to it — the same structural situation the retatrutide guide describes, reached here independently rather than by citing the same letter.
Research-grade survodutide, of the kind sold by the vendors Prof. Peptide tracks elsewhere on this site, is not a compounded drug product and not a branded product — those categories don’t apply to it at all. It is sold labeled for laboratory research use, not for human administration, and it is not dispensed against a prescription.
FAQ
Is there an FDA-approved survodutide product?
What dose did the Phase 3 SYNCHRONIZE trials use?
Is there a commonly reported survodutide starting dose outside the trials?
What were the most common side effects in the trials?
Can survodutide legally be compounded the way semaglutide or tirzepatide once were?
What does Prof. Peptide's own research-grade survodutide fall under, then?
References
- le Roux CW, Steen O, Lucas KJ, et al. Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial. Lancet Diabetes Endocrinol. 2024;12(3):162–173. ClinicalTrials.gov NCT04667377. https://clinicaltrials.gov/study/NCT04667377
- Sanyal AJ, Bedossa P, Fraessdorf M, et al. A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis. N Engl J Med. 2024;391(4):311–319. ClinicalTrials.gov NCT04771273. https://clinicaltrials.gov/study/NCT04771273
- Blüher M, Rosenstock J, Hoefler J, Manuel R, Hennige AM. Dose-response effects on HbA1c and bodyweight reduction of survodutide, a dual glucagon/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes: a randomised clinical trial. Diabetologia. 2024;67(3):470–482. ClinicalTrials.gov NCT04153929. https://clinicaltrials.gov/study/NCT04153929
- le Roux CW, Wharton S, Startseva E, et al. Survodutide Once Weekly for the Treatment of Adults with Obesity (SYNCHRONIZE-1). N Engl J Med. 2026;395(8):776–787. ClinicalTrials.gov NCT06066515. https://clinicaltrials.gov/study/NCT06066515
- Kaplan LM, Startseva E, le Roux CW, et al. Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE-MASLD, a randomized, double-blind, placebo-controlled phase 3 trial. Nat Med. 2026;32(8):2948–2958. ClinicalTrials.gov NCT06309992. https://clinicaltrials.gov/study/NCT06309992
- U.S. Food and Drug Administration. Warning Letter: GLP-1 Solution, reference 715883, 2025-09-09 (names retatrutide; does not name survodutide). https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/glp-1-solution-715883-09092025
- U.S. Food and Drug Administration. Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act. https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act
- U.S. Food and Drug Administration. 503B Bulk Drug Substances List. https://www.fda.gov/drugs/human-drug-compounding/503b-bulk-drug-substances-list
We may earn commissions from peptide vendor affiliate links.